BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

FDA accepted for filing and granted Priority Review to an NDA from Alimera for Iluvien to treat diabetic macular edema (DME). The company said...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >